Literature DB >> 25186912

Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction.

Manuela Corti1,2,3, Barbara K Smith1,4, Darin J Falk1, Lee Ann Lawson1, David D Fuller4, S H Subramony2, Barry J Byrne1,2, Evangelos A Christou4,3.   

Abstract

INTRODUCTION: Pompe disease is a progressive disease that affects skeletal muscles and leads to loss of ambulation. We investigated the activation of the tibialis anterior (TA) in late-onset Pompe disease (LOPD) individuals during maximal voluntary contraction (MVC) and evoked involuntary responses.
METHODS: Four LOPD patients and matched control subjects performed MVC of the TA using dorsiflexion and TA evoked responses. Activation of the TA was recorded with surface electromyography.
RESULTS: The Pompe patients exhibited greater power at frequencies below 60 Hz and reduced power above 100 Hz. They also exhibited a reduced increase in M-wave and prolonged M-wave latency and duration in response to stimulation.
CONCLUSIONS: These results provide evidence that LOPD individuals have an altered activation pattern of the TA during maximal contractions. The observed activation pattern may reflect impairments in voluntary command, neuromuscular junction pathology, or compensatory drive due to a reduced number of functional motoneurons.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Pompe disease; glycogen-storage disease; modulation; motoneuron; skeletal muscle

Mesh:

Year:  2015        PMID: 25186912      PMCID: PMC4348349          DOI: 10.1002/mus.24444

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  28 in total

1.  Rectification and non-linear pre-processing of EMG signals for cortico-muscular analysis.

Authors:  L J Myers; M Lowery; M O'Malley; C L Vaughan; C Heneghan; A St Clair Gibson; Y X R Harley; R Sreenivasan
Journal:  J Neurosci Methods       Date:  2003-04-15       Impact factor: 2.390

2.  Summation of forces from multiple motor units in the cat soleus muscle.

Authors:  Eric J Perreault; Scott J Day; Manuel Hulliger; C J Heckman; Thomas G Sandercock
Journal:  J Neurophysiol       Date:  2003-02       Impact factor: 2.714

Review 3.  The basics of electromyography.

Authors:  K R Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

4.  Age-related morphological changes in skeletal muscle cells of acid alpha-glucosidase knockout mice.

Authors:  Reinout P Hesselink; Gert Schaart; Anton J M Wagenmakers; Maarten R Drost; Ger J van der Vusse
Journal:  Muscle Nerve       Date:  2006-04       Impact factor: 3.217

Review 5.  The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings.

Authors:  Lisa D Hobson-Webb; Stephanie Dearmey; Priya S Kishnani
Journal:  Clin Neurophysiol       Date:  2011-05-13       Impact factor: 3.708

6.  A randomized study of alglucosidase alfa in late-onset Pompe's disease.

Authors:  Ans T van der Ploeg; Paula R Clemens; Deyanira Corzo; Diana M Escolar; Julaine Florence; Geert Jan Groeneveld; Serge Herson; Priya S Kishnani; Pascal Laforet; Stephen L Lake; Dale J Lange; Robert T Leshner; Jill E Mayhew; Claire Morgan; Kenkichi Nozaki; Dorothy J Park; Alan Pestronk; Barry Rosenbloom; Alison Skrinar; Carine I van Capelle; Nadine A van der Beek; Melissa Wasserstein; Sasa A Zivkovic
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

7.  [Late infantile form of Pompe's disease. Deficiency of alpha-1,4-glucosidase (acid maltase)].

Authors:  J Colomer; M Roig; J Campistol; G Rullan; E Fernández-Alvarez
Journal:  An Esp Pediatr       Date:  1984-09-15

8.  The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.

Authors:  P Laforêt; K Laloui; B Granger; D Hamroun; N Taouagh; J-Y Hogrel; D Orlikowski; F Bouhour; A Lacour; E Salort-Campana; I Penisson-Besnier; S Sacconi; F Zagnoli; F Chapon; B Eymard; C Desnuelle; J Pouget
Journal:  Rev Neurol (Paris)       Date:  2013-09-03       Impact factor: 2.607

Review 9.  The respiratory neuromuscular system in Pompe disease.

Authors:  David D Fuller; Mai K ElMallah; Barbara K Smith; Manuela Corti; Lee Ann Lawson; Darin J Falk; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2013-06-21       Impact factor: 1.931

10.  Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.

Authors:  B G H Schoser; J Müller-Höcker; R Horvath; K Gempel; D Pongratz; H Lochmüller; W Müller-Felber
Journal:  Neuropathol Appl Neurobiol       Date:  2007-06-15       Impact factor: 8.090

View more
  13 in total

1.  Electrodiagnostic Evaluation of Individuals Implanted With Extracellular Matrix for the Treatment of Volumetric Muscle Injury: Case Series.

Authors:  Nami Han; Mohammad A Yabroudi; Kristen Stearns-Reider; Wendy Helkowski; Brian M Sicari; J Peter Rubin; Stephen F Badylak; Michael L Boninger; Fabrisia Ambrosio
Journal:  Phys Ther       Date:  2015-11-12

2.  Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.

Authors:  Manuela Corti; Brian Cleaver; Nathalie Clément; Thomas J Conlon; Kaitlyn J Faris; Gensheng Wang; Janet Benson; Alice F Tarantal; Davis Fuller; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09       Impact factor: 5.032

3.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

Review 4.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

5.  Altered activation of the diaphragm in late-onset Pompe disease.

Authors:  Barbara K Smith; Manuela Corti; A Daniel Martin; David D Fuller; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2015-11-28       Impact factor: 1.931

6.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

7.  Motor planning perturbation: muscle activation and reaction time.

Authors:  Stefan Delmas; Agostina Casamento-Moran; Seoung Hoon Park; Basma Yacoubi; Evangelos A Christou
Journal:  J Neurophysiol       Date:  2018-06-27       Impact factor: 2.974

8.  Quantitative analysis of upright standing in adults with late-onset Pompe disease.

Authors:  Maria Stella Valle; Antonino Casabona; Agata Fiumara; Dora Castiglione; Giovanni Sorge; Matteo Cioni
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

9.  Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease.

Authors:  J Hordeaux; L Dubreil; C Robveille; J Deniaud; Q Pascal; B Dequéant; J Pailloux; L Lagalice; M Ledevin; C Babarit; P Costiou; F Jamme; M Fusellier; Y Mallem; C Ciron; C Huchet; C Caillaud; M-A Colle
Journal:  Acta Neuropathol Commun       Date:  2017-09-06       Impact factor: 7.801

10.  Case Studies in Neuroscience: Neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease.

Authors:  David D Fuller; Jorge A Trejo-Lopez; Anthony T Yachnis; Michael D Sunshine; Sabhya Rana; Victoria E Bindi; Barry J Byrne; Barbara K Smith
Journal:  J Neurophysiol       Date:  2021-06-30       Impact factor: 2.974

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.